KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Interest & Investment Income: 2016-2024

Historic Interest & Investment Income for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Dec 2024 value amounting to -$258.6 million.

  • Amneal Pharmaceuticals' Interest & Investment Income rose 4.12% to -$62.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$246.5 million, marking a year-over-year increase of 3.89%. This contributed to the annual value of -$258.6 million for FY2024, which is 22.77% down from last year.
  • Per Amneal Pharmaceuticals' latest filing, its Interest & Investment Income stood at -$258.6 million for FY2024, which was down 22.77% from -$210.6 million recorded in FY2023.
  • Amneal Pharmaceuticals' 5-year Interest & Investment Income high stood at -$136.3 million for FY2021, and its period low was -$258.6 million during FY2024.
  • Moreover, its 3-year median value for Interest & Investment Income was -$210.6 million (2023), whereas its average is -$209.2 million.
  • Per our database at Business Quant, Amneal Pharmaceuticals' Interest & Investment Income increased by 13.20% in 2020 and then tumbled by 32.99% in 2023.
  • Yearly analysis of 5 years shows Amneal Pharmaceuticals' Interest & Investment Income stood at -$146.0 million in 2020, then grew by 6.63% to -$136.3 million in 2021, then dropped by 16.18% to -$158.4 million in 2022, then slumped by 32.99% to -$210.6 million in 2023, then dropped by 22.77% to -$258.6 million in 2024.